Form 4: ALX Oncology Director Acquires 40,400 Shares Through Option Grant

Director Scott Garland acquired 40,400 shares of ALX Oncology through an option grant, vesting monthly starting February 21, 2025.

Summary

• Scott Garland, a director at ALX Oncology Holdings Inc., acquired 40,400 shares of common stock through an option grant.
• The options have an exercise price of $1.65 per share.
• The options vest in 12 equal monthly installments beginning on February 21, 2025.
• The grant was made on January 21, 2025, and the shares are exercisable until January 20, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows alignment of interests between management and shareholders. It is not a major event, but it is a positive sign.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard transaction for a director of a publicly traded company, often part of their compensation package.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in the biotechnology industry.
• The vesting schedule of 12 months is also typical for such grants.
• The exercise price is likely based on the market price of the stock at the time of the grant.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

ALX Oncology, stock options, insider trading, share acquisition, director, equity